Cognitive problems of breast cancer survivors on proton pump inhibitors
| Autor: | Brittney E. Bailey, Bhuvaneswari Ramaswamy, Robert Wesolowski, Maryam B. Lustberg, Nicole Williams, Jeffrey VanDeusen, Raquel E. Reinbolt, Janice K. Kiecolt-Glaser, Sagar Sardesai, Annelise A. Madison, William B. Malarkey, Alex Woody |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Cancer therapy Breast Neoplasms Article 03 medical and health sciences Cognition 0302 clinical medicine Breast cancer Cancer Survivors Quality of life Internal medicine Cognitive problems medicine Humans Cognitive Dysfunction Longitudinal Studies 030212 general & internal medicine Aged Aged 80 and over Oncology (nursing) business.industry Cancer Proton Pump Inhibitors Middle Aged medicine.disease Memory problems Checklist Oncology 030220 oncology & carcinogenesis Quality of Life Female business |
| Zdroj: | J Cancer Surviv |
| ISSN: | 1932-2267 1932-2259 |
| Popis: | PURPOSE: Proton pump inhibitors (PPIs) are used in cancer patients to manage treatment-related gastrointestinal symptoms and to prevent damage to the gastric mucosal lining during treatment. However, PPI use may contribute to cognitive problems. To compare PPI-users and non-users, breast cancer survivors reported cognitive problems in three studies. METHODS: In Study 1, breast cancer survivors (N=209; n=173 non-users, n=36 PPI-users; stages 0-IIIC) rated their cognitive function on the Kohli scale prior to cancer treatment, as well as one and two years later. In Study 2, women (N=200; n=169 non-users, n=31 PPI-users, stages 0-IIIa, M=11 months post-treatment) rated their cognitive function on the Kohli scale and BCPT checklist at three visits over a six-month period. In Study 3, participants (N=142; n=121 non-users, n=21 PPI-users; stages I-IIIa, M=4 years post-treatment) rated their cognitive function on the Kohli scale, BCPT checklist, and Functional Assessment of Cancer Therapy cognitive scale (FACT-cog). RESULTS: In Study 1, PPI-users reported more severe concentration problems (p=0.039) but not memory problems (p=0.17) than non-users. In Study 2, PPI-users reported more severe concentration problems (p=0.022) than non-users, but not memory problems or symptoms on the BCPT (ps=0.11). Study 3’s PPI-users reported more severe memory problems (p=0.002), poorer overall cognitive function (p=0.006), lower quality of life related to cognitive problems (p=0.005), greater perceived cognitive impairment (p=0.013), and poorer cognitive abilities (p=0.046), but not more severe concentration problems (p=0.16), compared to non-users. CONCLUSIONS/IMPLICATIONS: PPI use may impair breast cancer survivors’ memory, concentration, and quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink